scholarly journals Once-daily dose regimen of ribavirin is interchangeable with a twice-daily dose regimen: randomized open clinical trial

2015 ◽  
pp. 137
Author(s):  
Guido Haenen ◽  
Jiska Balk ◽  
Ron Peters ◽  
Aalt Bast ◽  
Wim van der Vijgh ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Dose Regimen ◽  
Once Daily ◽  
Daily Dose ◽  
Daily Dose Regimen

Treatment of hyperthyroidism with a small single daily dose of methimazole

1988 ◽  
Vol 119 (1) ◽  
pp. 139-144 ◽  
Author(s):  
Yasuo Mashio ◽  
Mutsuo Beniko ◽  
Akemi Ikota ◽  
Hiroaki Mizumoto ◽  
Haruhiko Kunita
Keyword(s):  
Divided Dose ◽  
Dose Regimen ◽  
Single Daily Dose ◽  
Once Daily ◽  
Daily Dose ◽  
The Mean ◽  
Time Required ◽  
Daily Dose Regimen ◽  
Mean Time ◽  
Immunoglobulin Levels

Abstract. A prospective randomized trial with the conventional divided doses (10 mg 3 times daily, N = 29) and a small single daily dose (15 mg once daily, N = 25) of methimazole for the treatment of Graves' hyperthyroidism was performed. Within 8 weeks, almost 80% of the patients in both groups became euthyroid. The mean time required to achieve the euthyroid state was 6.0 ± 2.8 and 6.0 ± 3.8 weeks, respectively. TSH binding inhibitor immunoglobulin was found in about 90% of the patients in both groups before methimazole treatment. However, a gradual fall of its levels was observed in nearly all patients after treatment. There was no difference in the mean levels of TSH binding inhibitor immunoglobulin between the two groups during therapy. We conclude that the single daily dose regimen of 15 mg of methimazole will control Graves' hyperthyroidism in most patients, and TSH binding inhibitor immunoglobulin levels decrease in this regimen in the same way as with the conventional divided dose regimen (10 mg 3 times daily).

Clinical and microbiological outcomes in treatment of men with non-gonococcal urethritis with a 100-mg twice-daily dose regimen of sitafloxacin

2012 ◽  
Vol 18 (3) ◽  
pp. 414-418 ◽  
Author(s):  
Shin Ito ◽  
Mitsuru Yasuda ◽  
Kensaku Seike ◽  
Takashi Sugawara ◽  
Tomohiro Tsuchiya ◽  
...  
Keyword(s):  
Dose Regimen ◽  
Gonococcal Urethritis ◽  
Daily Dose ◽  
Daily Dose Regimen

scholarly journals The Efficacy of Once-Daily Dose of Phenobarbital in Children with Generalized Tonic-Clonic Epilepsy

2018 ◽  
Vol 35 (7-8) ◽  
pp. 172-9
Author(s):  
Amril A. Burhany ◽  
Sofyan Ismael ◽  
Hardiono Pusponegoro
Keyword(s):  
Clinical Trial ◽  
Plasma Concentrations ◽  
Serum Levels ◽  
Control Group ◽  
Controlled Clinical Trial ◽  
Study Group ◽  
Once Daily ◽  
Daily Dose ◽  
Plasma Measurements ◽  
Better Than

In spite of its long half life, phenobarbital is still given twice-daily in the treatment of generalized tonic-clonic epilepsy. This study aims to determine if daily dose of phenobarbital given once differs to that given twice daily. Subjects of this unblinded controlled clinical trial were generalized tonic-clonic epilepsy patients ranging in age from 1-15 years. There were 40 study cases and 42 controls. We gave phenobarbital 4-6 mg/kg/day once-daily for study group and twice-daily dose for control group. History, physical and EEG examination and phenobarbital plasma measurements were obtained a t the beginning of the study and four weeks later. The ratio of the second to first phenobarbital plasma concentrations in the study group was 0.99 while in the control group it was 1.02. The proportion of seizure-free patients in the study group increased from 70% at the beginning to 85% at the end of study, and in the control group from 64.3% to 83.3%. Hyperactivity and irritability increased in both groups, and there were no significant differences in mean serum levels, seizures control, hyperactivity and irritability in both groups. Drowsiness was found in 50% of cases, but statistically significant decrease were found in study group. The compliance of the study group (92.5%) was significantly better than that of the control group (71.4%).

scholarly journals Efficacy of Once Daily versus Divided Daily Administration of Low Daily Dosage (15 mg/Day) of Methimazole in the Induction of Euthyroidism in Graves’ Hyperthyroidism: A Randomized Controlled Study

2017 ◽  
Vol 2017 ◽  
pp. 1-6 ◽  
Author(s):  
Sutin Sriussadaporn ◽  
Wanwaroon Pumchumpol ◽  
Raweewan Lertwattanarak ◽  
Tada Kunavisarut
Keyword(s):  
Controlled Study ◽  
Once Daily ◽  
Randomized Controlled ◽  
Daily Dose ◽  
Cumulative Rate ◽  
Baseline Characteristics ◽  
Serum Thyroid Hormone ◽  
Thyroid Hormone Levels ◽  
Daily Dose Regimen ◽  
Clinical Trials Registry

Background. Previous studies used unequal or high daily dosages of methimazole (MMI) to compare the efficacy of once daily dose regimen (OD-MMI) with that of divided daily doses regimen (DD-MMI) in inducing euthyroidism. Objectives. To compare the efficacy of OD-MMI to that of DD-MMI using low daily dosage of MMI in inducing euthyroidism. Methods. Fifty patients with clinically nonsevere Graves’ hyperthyroidism were randomized to be treated with 15 mg/day OD-MMI or 15 mg/day DD-MMI. Results. 21 cases (84%) in OD-MMI and 23 cases (92%) in DD-MMI were eligible for analyses. During the treatment, there was no difference in baseline characteristics, serum FT3 and FT4 reductions, and cumulative rate of achieving euthyroidism (4.8% versus 4.3%, 28.6% versus 34.8%, 71.4% versus 82.6%, and 85.7% versus 87.0% at 2, 4, 8, and 12 weeks, resp.) between both regimens. Hypothyroidism developed in DD-MMI significantly more than in OD-MMI (17.4% versus 0%, p<0.05). Conclusions. Treatment with MMI at a low daily dosage of 15 mg/day OD-MMI is as effective as DD-MMI in the reduction of serum thyroid hormone levels and induction of euthyroidism. The OD-MMI regimen is preferable to the DD-MMI regimen in the treatment of clinically nonsevere Graves’ hyperthyroidism. This trial is registered with Thai Clinical Trials Registry: TCTR20170529001.

The Antihypertensive Effect of Verapamil in Twice and Thrice Daily Dose Regimens. A Randomized, Double-Blind, Crossover Trial

1983 ◽  
Vol 11 (3) ◽  
pp. 190-193 ◽  
Author(s):  
B Hedbäck ◽  
K Parment
Keyword(s):  
Dose Regimen ◽  
Crossover Trial ◽  
Antihypertensive Effect ◽  
Morning Dose ◽  
Double Blind ◽  
Daily Dose ◽  
The Mean ◽  
Daily Dose Regimen ◽  
Blind Crossover Study ◽  
Double Blind Crossover Study

The antihypertensive effect of verapamil 200 mg b.i.d. was compared with that of verapamil 120 mg t.i.d. in a double-blind crossover study in eight out-patients with essential hypertension. The mean supine blood pressure measured before the morning dose was 150/87 mm Hg in patients treated with verapamil 200 mg b.i.d. and 151/87 mm Hg in those treated with verapamil 120 mg t.i.d. The recently reported prolonged half-life and accumulation of verapamil during steady-state conditions explains the lasting antihypertensive effect with the twice-daily dose regimen. Such a twice daily dose regimen is presumed to be more convenient to the patients and thus improve their compliance.

Once Daily Administration of Pindolol in the Treatment of Hypertension

1973 ◽  
Vol 1 (2) ◽  
pp. 465-469
Author(s):  
R C Dhatariya ◽  
A J Blowers
Keyword(s):  
Blood Pressure ◽  
Pressure Control ◽  
Moderate Essential Hypertension ◽  
Loss Of Control ◽  
Once Daily ◽  
Daily Dose ◽  
Treatment Of Hypertension ◽  
Previously Treated Patients ◽  
Previously Treated ◽  
Daily Dose Regimen

An open study was carried out in general practice on patients with mild to moderate essential hypertension to assess the effectiveness of treatment with pindolol on a single daily dose regimen. In twenty-two previously untreated cases given a single daily dosage of pindolol (mean 13.0 mg, range 5 mg −30 mg), adequate blood pressure control was achieved within five weeks and maintained in the nineteen patients examined at Week 25. Of eleven previously treated patients whose blood pressure was adequately controlled by divided daily doses of pindolol, a change-over to a single daily dosage of pindolol (mean 13.2 mg, range 10 mg − 20 mg) did not result in any loss of control over a twenty-five week study period. Few side-effects were reported, and only one patient was withdrawn from the study.

Sign in / Sign up

Export Citation Format

Share Document